Multichannel
Getting ready for primetime in cell & gene therapy
As thousands of novel cell and gene therapies advance along the development pipeline, pressure mounts for scalable treatments
Multichannel
Getting ready for primetime in cell & gene therapy
Cell and gene therapies (CGTs) have a lot going for them from an industry perspective – with a market predicted to reach US$50...
Multichannel
Scaling CGT through automation
Cell and gene therapies need to be made cheaper. Much cheaper. With price tags in the millions, they will never be able to deliver on their...
Latest
-
-
Commercial
Building a commercial dream team for today’s pharma industry
The transformation in the way pharma and HCPs interact is leading pharma companies to reorganize and rethink the makeup and approach of its commercialization teams -
Patients and Medical
Digital Health: Letting human nature drive design
End users are increasingly important partners in developing digital health solutions, to the benefit of all -
Access and Evidence
RWE’s new dataset: Social media
Pharma is waking up to the potential of social media to enhance existing RWD sources and to offer altogether new insights in rare disease and beyond -
Multichannel
Scaling CGT through automation
Delivering on the promise of cell and gene therapies requires significant process improvements to cut manufacturing time and costs
Most Popular
Brian Eastwood, (Dec 7, 2022)
The transformation in the way pharma and HCPs interact is leading pharma companies to reorganize and rethink the makeup and approach of its commercialization teams
Clare Jackson, (Dec 8, 2022)
As thousands of novel cell and gene therapies advance along the development pipeline, pressure mounts for scalable treatments
Andrew Stone, (Dec 21, 2022)
Still stuck in multichannel and too often serving up undifferentiated messaging, pharma has much to do to understand and serve individual HCPs
Opinion
Jill Donahue, (Sep 5, 2022)
For Ana Paula Carvalho, President of Western Europe Cluster, Pfizer, her purpose began amidst overcoming challenges.
Jill Donahue, (Feb 13, 2022)
Paying it forward and helping others act on their patient-driven purpose is the goal of this pharma leader
Commercial
-
Building a commercial dream team for today’s pharma industry
The transformation in the way pharma and HCPs interact is leading pharma companies to reorganize and rethink the makeup and approach of its commercialization teams -
Omnichannel: How will pharma get there?
The journey from multichannel to omnichannel requires closer data co-ordination, an agile approach, new metrics and nimbler content management -
Becoming agile in experience measurement
The customer experience is pharma’s new competitive battleground – trust is its key metric, and the prizes will go to the nimble -
Paving the payment path for DTx
The digital therapeutics reimbursement process is maturing but complexity and risk remain to be managed -
The field force: Is small beautiful?
As big pharma ponders the right sizing of its post-pandemic field forces, can it learn from smaller, leaner industry peers about doing more with less?
Access and Evidence
-
RWE’s new dataset: Social media
Pharma is waking up to the potential of social media to enhance existing RWD sources and to offer altogether new insights in rare disease and beyond -
How automation is changing regulatory affairs
Post pandemic, pharma and regulators are both working to accelerate the transformative power of electronic filing -
An early peek at the FDA’s RWE ‘cookbook’
The FDA is developing guidelines that will help pharma accelerate its adoption of RWE, this is what the industry should know -
The future is bright for RWE in pharma approvals
The FDA and other regulatory bodies are increasingly willing to accept real-world evidence as part of approvals. Pharma is up to the task -
Payers and the ABCs of digital literacy
Convincing payers of the value of digital add-ons and of drug/device combinations requires pharma to demonstrate that patients and other stakeholders understand how to use them
Patients and Medical
-
Digital Health: Letting human nature drive design
End users are increasingly important partners in developing digital health solutions, to the benefit of all -
Advancing health equity for the LGBTQIA+ community
Marginalised and with a range of unmet health needs, LGBTQIA+ patients are not getting the care they need. Pharma can help. -
Advocacy in Hemophilia: Building the Future by Design
Creating a visionary paradigm for the future of hemophilia and rare diseases that disrupts current thinking -
Bringing hope in hemophilia
By collaborating, gathering compelling global data and sharing knowledge hemophilia advocates are driving fairer and broader access to diagnosis and treatment -
Clinical trials: Japan’s next chapter
Post COVID-19, keeping patients at the center of plans for clinical trial design in Japan is vital
Latest Videos
Upcoming Events
View All EventsJanuary 2023
-
FREE REGULATORY PANEL: Even spaceships need a launchpad
Jan 31, 2023 - Jan 31, 2023
February 2023
-
FREE WEBINAR: Empower Better Patient Outcomes through True Digital Health Co-Creation
Feb 2, 2023 - Feb 2, 2023
-
FREE WEBINAR: Holistic Care at Scale
Feb 9, 2023 - Feb 9, 2023
-
FREE WEBINAR: Medical Affairs Data Centricity
Feb 16, 2023 - Feb 16, 2023
March 2023
-
Pharma USA 2023
Mar 28, 2023 - Mar 29, 2023
April 2023
-
Pharma Europe 2023
Apr 18, 2023 - Apr 20, 2023